Novo Nordisk shares plunge after investor day fails to deliver trial data

Novo Nordisk's share price dropped sharply on the Copenhagen exchange after an investor day that offered promises of new medicines but no concrete trial results. The market reacted negatively to the lack of near-term pipeline catalysts, underscoring investor impatience with the company's growth outlook beyond Ozempic. The decline signals a repricing of Novo's growth expectations, though the magnitude of the drop and any guidance changes remain unclear.